0001213900-22-046308.txt : 20220810 0001213900-22-046308.hdr.sgml : 20220810 20220810154827 ACCESSION NUMBER: 0001213900-22-046308 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 38 CONFORMED PERIOD OF REPORT: 20220630 FILED AS OF DATE: 20220810 DATE AS OF CHANGE: 20220810 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Joway Health Industries Group Inc CENTRAL INDEX KEY: 0001263364 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 980221494 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-108715 FILM NUMBER: 221151666 BUSINESS ADDRESS: STREET 1: NO 19 BAOWANG ROAD STREET 2: BAODI ECONOMIC DEVELOPMENT ZONE CITY: TIANJIN, PRC STATE: F4 ZIP: 300180 BUSINESS PHONE: 862258896888 MAIL ADDRESS: STREET 1: NO 19 BAOWANG ROAD STREET 2: BAODI ECONOMIC DEVELOPMENT ZONE CITY: TIANJIN, PRC STATE: F4 ZIP: 300180 FORMER COMPANY: FORMER CONFORMED NAME: G2 VENTURES INC DATE OF NAME CHANGE: 20030911 10-Q 1 f10q0622_jowayhealth.htm QUARTERLY REPORT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the Quarterly Period Ended June 30, 2022

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number: 333-108715

Joway Health Industries Group Inc.

(Exact Name of Registrant as Specified in Its Charter)

Nevada

98-0221494

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

600 South 3^rd Street

Las Vegas, Nevada 89101

(Address of principal executive offices) (Zip Code)

(702) 384-1990

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
None		N/A		N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File to be submitted posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company filer. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☒ No ☐

As of August 9, 2022, the registrant had 20,054,000 shares of common stock issued and outstanding.

JOWAY HEALTH INDUSTRIES GROUP INC.

QUARTERLY REPORT ON FORM 10-Q

June 30, 2022

TABLE OF CONTENTS

		PAGE
PART I - FINANCIAL INFORMATION		1

Item 1.	Financial Statements (unaudited)	1

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	5

Item 4.	Controls and Procedures	5

PART II - OTHER INFORMATION		6

Item 1.	Legal Proceedings	6

Item 1A.	Risk Factors	6

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	6

Item 3.	Defaults Upon Senior Securities	6

Item 4.	Mine Safety Disclosure	6

Item 5.	Other Information	6

Item 6.	Exhibits	6

SIGNATURES		7

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such forward-looking statements include, among others, those statements including the words “believes”, “anticipates”, “expects”, “intends”, “estimates”, “plans” and words of similar import. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Forward-looking statements are based on our current expectations and assumptions regarding our business, potential target businesses, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you therefore that you should not rely on any of these forward-looking statements as statements of historical fact or as guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include changes in local, regional, national or global political, economic, business, competitive, market (supply and demand) and regulatory conditions.

A description of these and other risks and uncertainties that could affect our business appears in the section captioned “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 which we filed with the Securities and Exchange Commission (“SEC”) on March 30, 2022 (the “Annual Report”). The risks and uncertainties described under “Risk Factors” are not exhaustive.

Given these uncertainties, readers of this Quarterly Report on Form 10-Q (“Quarterly Report”) are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future events or developments.

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements.

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States and the rules of the SEC, and should be read in conjunction with the audited financial statements and notes thereto contained in our Annual Report, as updated in subsequent filings we have made with the SEC. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the periods presented have been reflected herein. The results of operations for the periods presented are not necessarily indicative of the results to be expected for the full year.

JOWAY HEALTH INDUSTRIES GROUP INC.

FINANCIAL STATEMENTS

June 30, 2022 (UNAUDITED)

INDEX TO FINANCIAL STATEMENTS

Balance Sheets at June 30, 2022 (Unaudited) and December 31, 2021 (Audited)		F-1

Statements of Operations and Comprehensive Loss for Three and Six Months ended June 30, 2022 and 2021 (Unaudited)		F-2

Statements of Cash Flows for Six months ended June 30, 2022 and 2021 (Unaudited)		F-3

Notes to Financial Statements		F-4 - F-8

JOWAY HEALTH INDUSTRIES GROUP INC.

BALANCE SHEETS

	June 30,			December 31,
	2022			2021
	(Unaudited)			(Audited)
ASSETS

CURRENT ASSETS:
Total current assets		-			-
Total assets	$	-		$	-
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)

CURRENT LIABILITIES:
Other payables		143,682			103,053
Due to related parties		-			3,999
Total current liabilities		143,682			107,052

COMMITMENTS		-			-

STOCKHOLDERS’ EQUITY (DEFICIT):
Preferred stock - par value $0.001; 1,000,000 shares authorized; no shares issued and outstanding		-			-
Common stock - par value $0.001; 200,000,000 shares authorized; 20,054,000 shares issued and outstanding at June 30, 2022 and December 31, 2021		20,054			20,054
Additional paid-in-capital		7,232,861			7,228,862
Accumulated deficit		(7,396,597	)		(7,355,968	)
Total stockholders’ deficit		(143,682	)		(107,052	)
Total liabilities and stockholders’ equity (deficit)	$	-		$	-

The accompanying notes are an integral part of these financial statements

F-1

JOWAY HEALTH INDUSTRIES GROUP INC.

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)

	Three Months Ended June 30,						Six Months Ended June 30,
	2022			2021			2022			2021

REVENUES	$	-		$	-		$	-		$	-

COST OF REVENUES		-			-			-			-

GROSS PROFIT		-			-			-			-

General and administrative expenses		30,295			13,132			40,629			96,557
OPERATING EXPENSES		30,295			13,132			40,629			96,557

LOSS FROM OPERATIONS		(30,295	)		(13,132	)		(40,629	)		(96,557	)

Other expenses		-			-			-			-
OTHER LOSS, NET		-			-			-			-

LOSS BEFORE INCOME TAXES		(30,295	)		(13,132	)		(40,629	)		(96,557	)

INCOME TAXES		-			-			-			-

NET LOSS		(30,295	)		(13,132	)		(40,629	)		(96,557	)

OTHER COMPREHENSIVE LOSS:

COMPREHENSIVE LOSS	$	(30,295	)	$	(13,132	)	$	(40,629	)	$	(96,557	)

NET LOSS PER COMMON SHARE, BASIC AND DILUTED:	$	-		$	-			-		$	-

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING, BASIC AND DILUTED		20,054,000			20,054,000			20,054,000			20,054,000

The accompanying notes are an integral part of these financial statements

F-2

JOWAY HEALTH INDUSTRIES GROUP INC.

STATEMENTS OF CASH FLOWS

(UNAUDITED)

	Six Months Ended June 30,
	2022			2021

CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss from continuing operations	$	(40,629	)	$	(96,557	)
Adjustments to reconcile net loss to net cash used in operating activities
Changes in operating assets and liabilities:
Receivable from disposal of subsidiaries		-			119,070
Special dividend payable		-			(119,070	)
Other payables		40,629			29,560
Net cash used in operating activities		-			(66,997	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Net cash provided by investing activities		-			-

CASH FLOWS FROM FINANCING ACTIVITIES:
Due to related parties		-			66,997
Net cash provided by financing activities		-			66,997

EFFECT OF EXCHANGE RATE CHANGES ON CASH		-			-

NET INCREASE IN CASH		-			-

CASH, beginning of period		-			-

CASH, end of period	$	-		$	-

SUPPLEMENTAL DISCLOSURES:

Income taxes paid	$	-		$	-
Interest paid	$	-		$	-

The accompanying notes are an integral part of these financial statements

F-3

JOWAY HEALTH INDUSTRIES GROUP INC.

NOTES TO FINANCIAL STATEMENTS

(UNAUDITED)

NOTE 1 – ORGANIZATION

Joway Health Industries Group Inc. is herein referred to as “Joway Health”, the “Company,” “we” and “us”.

Joway Health (formerly G2 Ventures, Inc.) was originally incorporated under the laws of the State of Nevada on March 21, 2003.

On November 20, 2020, Joway Health entered into a Merger Agreement (the “Merger Agreement”) with Dynamic Elite International Limited, a British Virgin Islands company and a wholly-owned subsidiary of the Company (“Dynamic Elite”), Crystal Globe Limited, a British Virgin Islands company (“Parent”) and Joway Merger Subsidiary Limited, a British Virgin Islands company and a wholly-owned subsidiary of Parent (“Merger Sub”). Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into Dynamic Elite (the “Merger”), with Dynamic Elite continuing as the surviving corporation as a wholly-owned subsidiary of Parent. The special committee of the Board of Directors of the Company unanimously approved the Merger Agreement and the transactions contemplated thereby.

Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”) and as a result of the Merger, the ordinary shares of common stock of Dynamic Elite issued and outstanding immediately prior to the Effective Time, all of which are held by the Company, were cancelled and extinguished in consideration for $119,070 in cash (the “Merger Consideration”). The Company distributed the Merger Consideration to its shareholders (other than to Parent) in an amount equal to such shareholder’s proportionate share of the Merger Consideration based on such shareholders’ percentage of the outstanding common stock of the Company. In addition, the Company received a fairness opinion from an investment banker opining that the Merger Consideration was fair, from a financial point of view, to the shareholders of the Company.

As of December 31, 2020, the Effective Time of the Merger, the 10,000 ordinary shares of common stock of Dynamic Elite issued and outstanding immediately which were held by the Company, were cancelled for $119,070 in cash as Merger Consideration, or $0.45 per share. In January 2021, the Company had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders, other than Crystal Globe, which represented 2,646,000 shares of our common stock. Since the remaining 17,408,000 shares of our common stock was owned by Crystal Globe, the $0.045 per share payment for the 17,408,000 shares was offset and Crystal Globe did not receive any cash payment in connection with the Merger.

On December 31, 2020, upon the Company completed the Merger Agreement with Crystal Globe, Joway Health became a “shell company” (as such term is defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

Going forward, the Company intends to seek, investigate and, if such investigation warrants, engage in a business combination with a private entity whose business presents an opportunity for the Company’s stockholders.

NOTE 2 – GOING CONCERN

The accompanying unaudited financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the discharge of liabilities in the normal course of business for the foreseeable future.

As reflected in the accompanying unaudited financial statements, for the six months ended June 30, 2022 and 2021, we incurred net losses of $40,629 and $96,557, respectively. As of June 30, 2022, we had an accumulated deficit of $7.4 million. Management believes these factors raise substantial doubt about our ability to continue as a going concern for the next twelve months.

The continuation of our Company as a going concern through the next twelve months is dependent upon the continued financial support from our stockholders or external financing. Management believes that our existing stockholders will provide the additional cash to meet our obligations as they become due.

F-4

These conditions raise substantial doubt about our company’s ability to continue as a going concern. These financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of these uncertainties. Management believes that the actions presently being taken to obtain additional funding and implement its strategic plan provides the opportunity for our company to continue as a going concern.

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). After the consummation of the Merger as of December 31, 2020, the Company’s functional currency is USD.

Use of Estimates

The preparation of the financial statements is in conformity with generally accepted accounting principles in the United States of America, which require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made. Actual results could differ from those estimates.

Other Comprehensive Income

Other comprehensive income is defined as the change in equity during the period from transactions and other events, excluding the changes resulting from investments by owners and distributions to owners, and is not included in the computation of income tax expense or benefit. Accumulated other comprehensive income represents the accumulated balance of foreign currency translation adjustments.

Concentrations of Credit Risk

As a result of the consummation of the Merger, as of December 31, 2020, the Company became a shell company, as that term is defined in Rule 12b-2 of the Exchange Act of 1934, as amended (the “Exchange Act”). Going forward, our main business operations consist of seeking a business combination with a private entity whose business would present an opportunity for its shareholders.

Fair Value of Financial Instruments

Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

●

Level 1—defined as observable inputs such as quoted prices in active markets for identical assets or liabilities;

●

Level 2—defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and

●

Level 3—defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

The carrying amounts reported in the balance sheets for cash, accounts receivable, other receivable, accounts payable, other payable, and amounts due from related parties generally approximate their fair market values based on the short-term maturity of these instruments. ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments.

F-5

Revenue Recognition

The Company recognizes revenue when it satisfies a performance obligation by transferring a promised good or service to a customer or the customer obtains control of that asset, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those promised goods or services.

After the consummation of the Merger as of December 31, 2020, the Company did not report any revenue for the year ended December 31, 2021 or the first half year ending June 30, 2022.

Income Taxes

The Company accounts for income taxes in accordance with FASB ASC 740 “Income Taxes” (formerly SFAS No. 109 Accounting for Income Taxes), which is an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. ASC 740 additionally requires the establishment of a valuation allowance to reflect the likelihood of realization of deferred tax assets. Realization of deferred tax assets is dependent upon future earnings, if any, of which the timing and amount are uncertain.

According to ASC 740, the evaluation of a tax position is a two-step process. The first step is to determine whether it is more likely than not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigation based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50% likelihood of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer met. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition.

Basic and Diluted Earnings per Share

The Company reports earnings per share in accordance with FASB ASC 260 “Earnings per share”. The Company’s basic earnings per share are computed using the weighted average number of shares outstanding for the periods presented. Diluted earnings per share are computed based on the assumption that any dilutive options or warrants were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, the Company’s outstanding stock warrants are assumed to be exercised, and funds thus obtained were assumed to be used to purchase common stock at the average market price during the period. There were no dilutive instruments outstanding during the three month and six month periods ended June 30, 2022 and 2021.

Recently Issued Accounting Pronouncements

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company adopted the standard in 2021. Adoption of the standard did not have a significant impact on the Company’s statement of earnings in 2021.

F-6

Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s consolidated financial statements upon adoption.

Deconsolidation

On November 20, 2020, Joway Health entered into a Merger Agreement (the “Merger Agreement”) with Dynamic Elite International Limited, a British Virgin Islands company and a wholly-owned subsidiary of the Company (“Dynamic Elite”), Crystal Globe Limited, a British Virgin Islands company (“Crystal Globe”) and Joway Merger Subsidiary Limited, a British Virgin Islands company and a wholly-owned subsidiary of Crystal Globe (“Merger Sub”). The Merger Agreement provides that, upon the terms and subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will be merged with and into Dynamic Elite (the “Merger”), with Dynamic Elite continuing as the surviving corporation as a wholly-owned subsidiary of Crystal Globe.

Crystal Globe, as the majority shareholder holding approximately 86.81% of the Company, is also the sole shareholder of Dynamic Elite after the Merger. Mr. Jinghe Zhang, as the former President, former Chief Executive Officer, former Chairman and Director, and the majority beneficial owner of the Company, also serves as sole shareholder and executive director of Crystal Globe. As a result, the Company and Dynamic Elite are under common control of Crystal Globe and Mr. Jinghe Zhang.

Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”) and as a result of the Merger, the ordinary shares of common stock of Dynamic Elite issued and outstanding immediately prior to the Effective Time, all of which are held by the Company, will be cancelled and extinguished. In accordance with the Merger Agreement, Crystal Globe has offered a cash consideration of $0.045 per share for outstanding shares of Joway Health’s common stock (the “Merger Consideration”). As of November 20, 2020, Joway Health reported 20,054,000 shares of common stock outstanding. As a result, Joway Health recognized a loss of $1,340,795 from this transaction.

In January 2021, Joway Health had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders, other than Crystal Globe, which represents 2,646,000 shares of Joway Health’s common stock. Since the remaining 17,408,000 shares of Joway Health’s common stock is owned by Crystal Globe, the $0.045 per share payment for the 17,408,000 shares is offset.

The following is a reconciliation of the deconsolidation:

	Amount
Selling price	$	902,430
Disposed assets and liabilities:
Cash		79,446
Current assets		1,133,812
Fixed assets		3,194,533
Intangible assets		465,007
Liabilities		(1,977,822	)
Accumulated other comprehensive income		(651,751	)
		2,243,225
Loss from disposal of discontinued component, net of income tax	$	(1,340,795	)

NOTE 4 – OTHER PAYABLES

As of June 30, 2022 and December 31, 2021, the Company reported $143,682 and $103,053 as its other payables, respectively. The other payables mainly consist of payables for professional services, including audit, legal, and financial statement filing services.

F-7

NOTE 5 – RELATED PARTY TRANSACTIONS

Payables due to related parties consist of the following:

	June 30,		December 31,
	2022		2021
Jinghe Zhang	$	-	$	3,999
Total	$	-	$	3,999

The amounts owed to related parties are non-interest bearing and have no specified repayment terms.

Transactions with Jinghe Zhang

The Company was a shell company and has no cash, Mr. Jinghe Zhang, our former President, former Chief Executive Officer and director, agreed to advance operating capital to the Company. For the three months ended March 31, 2022, Mr. Jinghe Zhang released the Company from $3,999.19 of indebtedness owed to him. For the three months ended March 31, 2021, the Company received $3,397 from Mr. Jinghe Zhang. As of June 30, 2022 and December 31, 2021, the total unpaid principal balance due to Mr. Jinghe Zhang for advances was $0 and $3,999, respectively.

NOTE 6 – INCOME TAXES

Upon the Company executed the Merger Agreement on December 31, 2020, no provision was made for federal income taxes since the Company has significant net operating losses.

The Company’s income tax returns since inception are subject to audit by regulatory authorities. Changes in tax laws and rates could also affect recorded deferred tax assets and liabilities in the future. Management is not aware of any such changes that would have a material effect on the Company’s results of operations, cash flows or financial position. The calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations. FASB ASC Topic 740, Income Taxes provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. ASC Topic 740 also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition.

We recognize tax liabilities in accordance with ASC Topic 740 and we adjust these liabilities when our judgment changes as a result of the evaluation of new information not previously available. Due to the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from our current estimate of the tax liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which they are determined.

NOTE 7 – SUBSEQUENT EVENTS

None

F-8

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

Forward-Looking Statements

The following management’s discussion and analysis should be read in conjunction with our historical financial statements and the related notes thereto. The management’s discussion and analysis contain forward-looking statements, such as statements of our plans, objectives, expectations and intentions. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. These forward-looking statements are subject to risks and uncertainties, including those under “Risk Factors” in our Annual Report filed with the SEC on March 30, 2022, as updated in subsequent filings we have made with the SEC that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. Our actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors. We do not undertake any obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this Quarterly Report.

Basis of Presentation

The following discussion highlights our results of operations and the principal factors that have affected our financial condition as well as our liquidity and capital resources for the periods described, and provides information that management believes is relevant for an assessment and understanding of the statements of financial condition and results of operations presented herein. The following discussion and analysis are based on our unaudited financial statements contained in this Quarterly Report, which we have prepared in accordance with United States generally accepted accounting principles. You should read the discussion and analysis together with such financial statements and the related notes thereto.

Overview

Joway Health Industries Group Inc. (the Company, us or we) was incorporated in the state of Nevada. As of December 31, 2020, we become a shell company. The Company will promptly file a Current Report on Form 8-K when, and if, its status as a shell company changes.

The Company has no specific plans or proposals at this time which relate to or would result in:

	●	the acquisition by any person of additional securities of the Company;

	●	an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Company or any of its subsidiaries;

	●	a sale or transfer of a material amount of assets of the Company or of any of its subsidiaries;

	●	any material change in the present capitalization or dividend policy of the Company;

	●	any other material change in the Company’s business or corporate structure;

	●	changes in the Company’s charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the issuer by any other person;

	●	causing a class of securities of the Company to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;

	●	a class of equity securities of the Company becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Act of 1933, as amended; or

●

any similar action to those enumerated above.

Change in Control

On February 3, 2022, the Company consummated the transactions contemplated by the Stock Purchase Agreement dated as of January 31, 2022 (the “Purchase Agreement”), by and among the Company, Crystal Globe Limited, a British Virgin Island company (“Crystal Globe”) and JHP Holdings, Inc., a Nevada corporation (“JHP”), pursuant to which JHP purchased 16,644,820 shares of common stock of the Company from Crystal Globe. The shares represent 83% of the issued and outstanding shares of the Company on a fully diluted basis. The purchase price for the shares paid by JHP was $100,000. Pursuant to the Purchase Agreement, each of Crystal Globe, JHP and Company made customary representations and warranties to each other. The parties agreed to certain customary post-closing covenants, including those relating to confidentiality, publicity and litigation support. The Company and Crystal Globe also agreed to certain indemnification provisions as they pertain to JHP for breaches or inaccuracies in their respective representations and warranties or covenants.

In connection with the acquisition of the 83% by JHP, Jinghe Zhang, the sole officer and director of the Company, resigned and JHP appointed Ramon Lata as the President, Treasurer and Secretary and sole director of the Company. The executive offices of the Company are currently located at 600 South 3^rd Street, Las Vegas, Nevada 89101.

Results of Operations

Results of Operations - Three Months Ended June 30, 2022 Compared to Three Months Ended June 30, 2021

Revenues

During the three-month period ended June 30, 2022 and 2021, we did not realize any revenues from operations.

Expenses

Operating expenses, consisting entirely of general and administrative expenses (including professional fees) totaled $30,295 in the three-month period ended June 30, 2022, compared to $13,132 in the three-month period ended June 30, 2021. The increase of our operating expenses was mainly from the increase of our DTC service fee.

Net Loss

We incurred a net loss of $30,295, for the three months ended June 30, 2022, compared to a net loss of $13,132 for the corresponding period ended June 30, 2021.

Results of Operations – Six Months Ended June 30, 2022 Compared to Three Months Ended June 30, 2021

Revenues

During the six-month period ended June 30, 2022 and 2021, we did not realize any revenues from operations.

Expenses

Operating expenses, consisting entirely of general and administrative expenses (including professional fees) totaled $40,629 during the six months ended June 30, 2022, compared to $96,557 in same period ended June 30, 2021. The reduction of our operating expenses was mainly due to the decrease of audit fee.

Net Loss

We incurred a net loss of $40,629, for the six months ended June 30, 2022, compared to a net loss of $96,557 for the corresponding period ended June 30, 2021.

Liquidity and Capital Resources

As of June 30, 2022, we had no cash, liabilities of $143,682, and our working capital deficit was $143,682. Our current liquidity is not sufficient to meet the obligations associated with being a company that is fully reporting with the SEC.

To date, we have managed to keep our monthly cash flow requirement low for two reasons. First, our sole officer does not draw a salary at this time. Second, we have been able to keep our operating expenses to a minimum by operating in space provided at no expense by one of our shareholders.

We currently have no external sources of liquidity such as arrangements with credit institutions or off-balance sheet arrangements that will have or are reasonably likely to have a current or future effect on our financial condition or immediate access to capital.

Our directors and officers have made no commitments written or oral, with respect to providing a source of liquidity in the form of cash advances, loans and/or financial guarantees.

We expect that we will need to raise funds in order to effectuate our business plan. We anticipate that we will need to seek financing through means such as borrowings from institutions or private individuals. There can be no assurance that we will be able to raise such funds. If we are unsuccessful at raising sufficient funds, for whatever reason, to fund our operations, we may be forced to seek a buyer for our business or another entity with which we could create a joint venture. If all of these alternatives fail, we expect that we will be required to seek protection from creditors under applicable bankruptcy laws.

We have a history of operating losses and negative cash flow. These conditions raise substantial doubt about our ability to meet all of our obligations over the twelve months following the filing of this Form 10-Q. Management has evaluated these conditions and concluded that current plans will alleviate this concern. We currently have no debt other than advances from a shareholder and have no reason to believe that the shareholder will cease advancing the Company operating capital.

Our ability to continue as a going concern is dependent on our ability to implement our business plan, raise capital and generate revenues. See Note 2 of our financial statements.

Off-Balance Sheet Arrangements

We have never entered into any off-balance sheet financing arrangements and have not formed any special purpose entities. We have not guaranteed any debt or commitments of other entities or entered into any options on non-financial assets.

Contractual Obligations

None.

Recent Accounting Pronouncements

We do not anticipate that the adoption of recently issued accounting pronouncements to have a material effect on our condensed consolidated financial statements.

Going Concern

The accompanying unaudited condensed financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates continuity of operations, realization of assets, and liquidation of liabilities in the normal course of business. As reflected in the accompanying unaudited condensed financial statements, the Company had an accumulated deficit of $7.4 million and a working capital deficit of approximately $143,682 at June 30, 2022, and has incurred losses for all periods presented. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company’s ability to raise additional capital and implement its business plan, which is now to seek and develop a new sale strategy to enhance our sale force. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Management intends to provide the Company with additional loans as needed. Management feels these actions provide the opportunity for the Company to continue as a going concern.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

None.

ITEM 4. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

Our management, under the supervision and with the participation of our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), has evaluated the effectiveness of our disclosure controls and procedures as defined in SEC Rules 13a-15(e) and 15d-15(e) as of the end of the period covered by this quarterly report. The purpose of this evaluation is to determine if, as of June 30, 2022, our disclosure controls and procedures were operating effectively such that the information, required to be disclosed in our Securities and Exchange Commission (“SEC”) reports (i) was recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and (ii) was accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Based on their evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of June 30, 2022, our disclosure controls and procedures were not effective, based on the material weakness described below:

We did not have sufficient skilled accounting personnel that are either qualified as Certified Public Accountants in the U.S. or that have received education from U.S. institutions or other educational programs that would provide enough relevant education relating to U.S. GAAP.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting for the three months ended June 30, 2022 that materially affected, or are reasonably likely to materially affect our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

We know of no material, active, pending or threatened proceeding against us or our subsidiaries, nor are we, or any subsidiary, involved as a plaintiff or defendant in any material proceeding or pending litigation.

ITEM 1A. RISK FACTORS.

Not required for smaller reporting companies.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURES.

Not applicable.

ITEM 5. OTHER INFORMATION.

ITEM 6. EXHIBITS.

Exhibit No.		Description

31.1		Certification of Principal Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*

32.1		Certifications of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

101.INS		Inline XBRL Instance Document*

101.SCH		Inline XBRL Taxonomy Extension Schema Document*

101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document*

101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document*

101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document*

101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document*

104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

*	Filed herewith

Document has been furnished, is not deemed filed and is not to be incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, irrespective of any general incorporation language contained in any such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	JOWAY HEALTH INDUSTRIES GROUP INC.

Dated: August 10, 2022	By:	/s/ Ramon Lata
		Ramon Lata President (principal executive officer and principal financial and accounting officer)

EX-31.1 2 f10q0622ex31-1_jowayhealth.htm CERTIFICATION

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

OF REGISTRANT PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

(RULE 13a-14(a) or 15d-14(a) OF THE EXCHANGE ACT)

I, Ramon Lata, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Joway Health Industries Group Inc.;

Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3.	Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly for the period in which this quarterly report is being prepared;

[Paragraph omitted pursuant to SEC Release Nos. 33-8238/34-47986 and 33-8392/34-49313];

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

all significant deficiencies in the design or operation of internal controls which could adversely affect the registrant’s ability to record, process, summarize and report financial data and have identified for the registrant’s auditors any material weaknesses in internal controls; and

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

	/s/ Ramon Lata
Dated: August 10, 2022	Name: Ramon Lata
	Title: President
	(Principal Executive Officer and Principal Financial and Accounting Officer)

EX-32.1 3 f10q0622ex32-1_jowayhealth.htm CERTIFICATION

Exhibit 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

In connection with this quarterly report on Form 10-Q of Joway Health Industries Group Inc. (the “Company”) as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacity and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

Dated: August 10, 2022	/s/ Ramon Lata
	Name: Ramon Lata
	Title: President
	(Principal Executive Officer and Principal Financial and Accounting Officer)

EX-101.SCH 4 gtvi-20220630.xsd XBRL SCHEMA FILE 001 - Statement - Balance Sheets link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Balance Sheets (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - Organization link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Going Concern link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Other Payables link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Related Party Transactions (Tables) link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Organization (Details) link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Going Concern (Details) link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of reconciliation of the deconsolidation link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Other Payables (Details) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Related Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Related Party Transactions (Details) - Schedule of payables due to related parties link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 5 gtvi-20220630_cal.xml XBRL CALCULATION FILE EX-101.DEF 6 gtvi-20220630_def.xml XBRL DEFINITION FILE EX-101.LAB 7 gtvi-20220630_lab.xml XBRL LABEL FILE Statement of Financial Position [Abstract] Total assets Total current liabilities Total stockholders’ deficit Total liabilities and stockholders’ equity (deficit) Income Statement [Abstract] GROSS PROFIT OPERATING EXPENSES LOSS FROM OPERATIONS OTHER LOSS, NET LOSS BEFORE INCOME TAXES NET LOSS COMPREHENSIVE LOSS Statement of Cash Flows [Abstract] Net cash used in operating activities Net cash provided by financing activities NET INCREASE IN CASH CASH, beginning of period CASH, end of period Accounting Policies [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Schedule of reconciliation of the deconsolidation [Abstract] Other Payables [Abstract] Related Party Transactions [Abstract] Schedule of payables due to related parties [Abstract] Related Party [Axis] Income Tax Disclosure [Abstract] Subsequent Events [Abstract] Document Type Document Quarterly Report Document Period End Date Document Fiscal Year Focus Document Transition Report Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Amendment Flag Current Fiscal Year End Date Document Fiscal Period Focus Entity Central Index Key ASSETS CURRENT ASSETS: LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) CURRENT LIABILITIES: Other payables Due to related parties COMMITMENTS STOCKHOLDERS’ EQUITY (DEFICIT): Preferred stock - par value $0.001; 1,000,000 shares authorized; no shares issued and outstanding Preferred stock, par value (in Dollars per share) Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock - par value $0.001; 200,000,000 shares authorized; 20,054,000 shares issued and outstanding at June 30, 2022 and December 31, 2021 Common stock, par value (in Dollars per share) Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Additional paid-in-capital Accumulated deficit REVENUES COST OF REVENUES INCOME TAXES OTHER COMPREHENSIVE LOSS: NET LOSS PER COMMON SHARE, BASIC AND DILUTED: (in Dollars per share) NET LOSS PER COMMON SHARE, DILUTED WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING, BASIC AND DILUTED (in Shares) WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING, DILUTED CASH FLOWS FROM OPERATING ACTIVITIES: Net loss from continuing operations Adjustments to reconcile net loss to net cash used in operating activities Changes in operating assets and liabilities: Receivable from disposal of subsidiaries Other payables CASH FLOWS FROM INVESTING ACTIVITIES: Net cash provided by investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Due to related parties EFFECT OF EXCHANGE RATE CHANGES ON CASH SUPPLEMENTAL DISCLOSURES: Income taxes paid Interest paid Total current assets General and administrative expenses Other expenses Special dividend payable ORGANIZATION GOING CONCERN SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Schedule of reconciliation of the deconsolidation Selling price Disposed assets and liabilities: Cash Current assets Fixed assets Intangible assets Accumulated other comprehensive income Loss from disposal of discontinued component, gross of income tax Loss from disposal of discontinued component, net of income tax OTHER PAYABLES RELATED PARTY TRANSACTIONS Schedule of payables due to related parties Total INCOME TAXES SUBSEQUENT EVENTS Liabilities Jinghe Zhang [Member] Award Type [Axis] Legal Entity [Axis] Related Party Transaction [Axis] Cash (in Dollars) Common stock issued Per share (in Dollars per share) Cash received (in Dollars) Shares issued Incurred net losses Accumulated deficit Shareholder holding percentage Cash consideration per share (in Dollars per share) Common stock, shares outstanding Transaction loss (in Dollars) Cash received (in Dollars) Common stock shares Payment per share (in Dollars per share) Offset shares Other payables Related party released amount Unpaid principle amount advance Basis of Presentation Use of Estimates Other Comprehensive Income Concentrations of Credit Risk Fair Value of Financial Instruments Revenue Recognition Income Taxes Basic and Diluted Earnings per Share Recently Issued Accounting Pronouncements Deconsolidation Crystal Globe [Member] Joway Health [Member] Going Concern [Table] Going Concern [Abstract] Related Party [Domain] Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Award Type [Domain] Organization (Details) [Table] Organization (Details) [Line Items] Going Concern (Details) [Table] Going Concern (Details) [Line Items] Entity [Domain] Summary of Significant Accounting Policies (Details) [Table] Summary of Significant Accounting Policies (Details) [Line Items] Related Party Transaction [Domain] Related Party Transactions (Details) [Table] Related Party Transactions (Details) [Line Items] EX-101.PRE 8 gtvi-20220630_pre.xml XBRL PRESENTATION FILE XML 9 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Jun. 30, 2022	Aug. 09, 2022
Document Information Line Items
Entity Registrant Name	Joway Health Industries Group Inc.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		20,054,000
Amendment Flag	false
Entity Central Index Key	0001263364
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Jun. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	true
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	333-108715
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	98-0221494
Entity Address, Address Line One	600 South
Entity Address, Address Line Two	3rd Street
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89101
City Area Code	(702)
Local Phone Number	384-1990
Entity Interactive Data Current	Yes

XML 10 R2.htm IDEA: XBRL DOCUMENT

Balance Sheets - USD ($)	Jun. 30, 2022	Dec. 31, 2021
CURRENT ASSETS:
Total current assets
Total assets
CURRENT LIABILITIES:
Other payables	143,682	103,053
Due to related parties		3,999
Total current liabilities	143,682	107,052
COMMITMENTS
STOCKHOLDERS’ EQUITY (DEFICIT):
Preferred stock - par value $0.001; 1,000,000 shares authorized; no shares issued and outstanding
Common stock - par value $0.001; 200,000,000 shares authorized; 20,054,000 shares issued and outstanding at June 30, 2022 and December 31, 2021	20,054	20,054
Additional paid-in-capital	7,232,861	7,228,862
Accumulated deficit	(7,396,597)	(7,355,968)
Total stockholders’ deficit	(143,682)	(107,052)
Total liabilities and stockholders’ equity (deficit)

XML 11 R3.htm IDEA: XBRL DOCUMENT

Balance Sheets (Parentheticals) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	20,054,000	20,054,000
Common stock, shares outstanding	20,054,000	20,054,000

XML 12 R4.htm IDEA: XBRL DOCUMENT

Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
REVENUES
COST OF REVENUES
GROSS PROFIT
General and administrative expenses	30,295	13,132	40,629	96,557
OPERATING EXPENSES	30,295	13,132	40,629	96,557
LOSS FROM OPERATIONS	(30,295)	(13,132)	(40,629)	(96,557)
Other expenses
OTHER LOSS, NET
LOSS BEFORE INCOME TAXES	(30,295)	(13,132)	(40,629)	(96,557)
INCOME TAXES
NET LOSS	(30,295)	(13,132)	(40,629)	(96,557)
OTHER COMPREHENSIVE LOSS:
COMPREHENSIVE LOSS	$ (30,295)	$ (13,132)	$ (40,629)	$ (96,557)
NET LOSS PER COMMON SHARE, BASIC AND DILUTED: (in Dollars per share)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING, BASIC AND DILUTED (in Shares)	20,054,000	20,054,000	20,054,000	20,054,000

XML 13 R5.htm IDEA: XBRL DOCUMENT

Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
NET LOSS PER COMMON SHARE, DILUTED
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING, DILUTED	20,054,000	20,054,000	20,054,000	20,054,000

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

+ Details

XML 14 R6.htm IDEA: XBRL DOCUMENT

Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
Statements of Cash Flows (Unaudited) - USD ($)	Jun. 30, 2022	Jun. 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss from continuing operations	$ (40,629)	$ (96,557)
Adjustments to reconcile net loss to net cash used in operating activities
Receivable from disposal of subsidiaries		119,070
Special dividend payable		(119,070)
Other payables	40,629	29,560
Net cash used in operating activities		(66,997)
CASH FLOWS FROM INVESTING ACTIVITIES:
Net cash provided by investing activities
CASH FLOWS FROM FINANCING ACTIVITIES:
Due to related parties		66,997
Net cash provided by financing activities		66,997
EFFECT OF EXCHANGE RATE CHANGES ON CASH
NET INCREASE IN CASH
CASH, beginning of period
CASH, end of period
SUPPLEMENTAL DISCLOSURES:
Income taxes paid
Interest paid

XML 15 R7.htm IDEA: XBRL DOCUMENT

Organization

6 Months Ended

Jun. 30, 2022

Accounting Policies [Abstract]

ORGANIZATION

NOTE 1 – ORGANIZATION

Joway Health Industries Group Inc. is herein referred to as “Joway Health”, the “Company,” “we” and “us”.

Joway Health (formerly G2 Ventures, Inc.) was originally incorporated under the laws of the State of Nevada on March 21, 2003.

XML 16 R8.htm IDEA: XBRL DOCUMENT

Going Concern

6 Months Ended

Jun. 30, 2022

Going Concern [Abstract]

GOING CONCERN

NOTE 2 – GOING CONCERN

XML 17 R9.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2022

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

Use of Estimates

Other Comprehensive Income

Concentrations of Credit Risk

Fair Value of Financial Instruments

●

Level 1—defined as observable inputs such as quoted prices in active markets for identical assets or liabilities;

●

Level 2—defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and

●

Level 3—defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

Revenue Recognition

After the consummation of the Merger as of December 31, 2020, the Company did not report any revenue for the year ended December 31, 2021 or the first half year ending June 30, 2022.

Income Taxes

Basic and Diluted Earnings per Share

Recently Issued Accounting Pronouncements

Deconsolidation

On November 20, 2020, Joway Health entered into a Merger Agreement (the “Merger Agreement”) with Dynamic Elite International Limited, a British Virgin Islands company and a wholly-owned subsidiary of the Company (“Dynamic Elite”), Crystal Globe Limited, a British Virgin Islands company (“Crystal Globe”) and Joway Merger Subsidiary Limited, a British Virgin Islands company and a wholly-owned subsidiary of Crystal Globe (“Merger Sub”). The Merger Agreement provides that, upon the terms and subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will be merged with and into Dynamic Elite (the “Merger”), with Dynamic Elite continuing as the surviving corporation as a wholly-owned subsidiary of Crystal Globe.

Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”) and as a result of the Merger, the ordinary shares of common stock of Dynamic Elite issued and outstanding immediately prior to the Effective Time, all of which are held by the Company, will be cancelled and extinguished. In accordance with the Merger Agreement, Crystal Globe has offered a cash consideration of $0.045 per share for outstanding shares of Joway Health’s common stock (the “Merger Consideration”). As of November 20, 2020, Joway Health reported 20,054,000 shares of common stock outstanding. As a result, Joway Health recognized a loss of $1,340,795 from this transaction.

The following is a reconciliation of the deconsolidation:

	Amount
Selling price	$	902,430
Disposed assets and liabilities:
Cash		79,446
Current assets		1,133,812
Fixed assets		3,194,533
Intangible assets		465,007
Liabilities		(1,977,822	)
Accumulated other comprehensive income		(651,751	)
		2,243,225
Loss from disposal of discontinued component, net of income tax	$	(1,340,795	)

XML 18 R10.htm IDEA: XBRL DOCUMENT

Other Payables

6 Months Ended

Jun. 30, 2022

Other Payables [Abstract]

OTHER PAYABLES

NOTE 4 – OTHER PAYABLES

XML 19 R11.htm IDEA: XBRL DOCUMENT

Related Party Transactions

6 Months Ended

Jun. 30, 2022

RELATED PARTY TRANSACTIONS

NOTE 5 – RELATED PARTY TRANSACTIONS

Payables due to related parties consist of the following:

	June 30,		December 31,
	2022		2021
Jinghe Zhang	$	-	$	3,999
Total	$	-	$	3,999

The amounts owed to related parties are non-interest bearing and have no specified repayment terms.

Transactions with Jinghe Zhang

XML 20 R12.htm IDEA: XBRL DOCUMENT

Income Taxes

6 Months Ended

Jun. 30, 2022

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 6 – INCOME TAXES

Upon the Company executed the Merger Agreement on December 31, 2020, no provision was made for federal income taxes since the Company has significant net operating losses.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

XML 21 R13.htm IDEA: XBRL DOCUMENT

Subsequent Events

6 Months Ended

Jun. 30, 2022

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 7 – SUBSEQUENT EVENTS

None

XML 22 R14.htm IDEA: XBRL DOCUMENT

Accounting Policies, by Policy (Policies)

6 Months Ended

Jun. 30, 2022

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

Use of Estimates

Use of Estimates

Other Comprehensive Income

Other Comprehensive Income

Concentrations of Credit Risk

Concentrations of Credit Risk

Fair Value of Financial Instruments

Fair Value of Financial Instruments

●

Level 1—defined as observable inputs such as quoted prices in active markets for identical assets or liabilities;

●

Level 2—defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and

●

Level 3—defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

Revenue Recognition

Revenue Recognition

After the consummation of the Merger as of December 31, 2020, the Company did not report any revenue for the year ended December 31, 2021 or the first half year ending June 30, 2022.

Income Taxes

Income Taxes

Basic and Diluted Earnings per Share

Basic and Diluted Earnings per Share

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

Deconsolidation

Deconsolidation

On November 20, 2020, Joway Health entered into a Merger Agreement (the “Merger Agreement”) with Dynamic Elite International Limited, a British Virgin Islands company and a wholly-owned subsidiary of the Company (“Dynamic Elite”), Crystal Globe Limited, a British Virgin Islands company (“Crystal Globe”) and Joway Merger Subsidiary Limited, a British Virgin Islands company and a wholly-owned subsidiary of Crystal Globe (“Merger Sub”). The Merger Agreement provides that, upon the terms and subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will be merged with and into Dynamic Elite (the “Merger”), with Dynamic Elite continuing as the surviving corporation as a wholly-owned subsidiary of Crystal Globe.

Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”) and as a result of the Merger, the ordinary shares of common stock of Dynamic Elite issued and outstanding immediately prior to the Effective Time, all of which are held by the Company, will be cancelled and extinguished. In accordance with the Merger Agreement, Crystal Globe has offered a cash consideration of $0.045 per share for outstanding shares of Joway Health’s common stock (the “Merger Consideration”). As of November 20, 2020, Joway Health reported 20,054,000 shares of common stock outstanding. As a result, Joway Health recognized a loss of $1,340,795 from this transaction.

The following is a reconciliation of the deconsolidation:

	Amount
Selling price	$	902,430
Disposed assets and liabilities:
Cash		79,446
Current assets		1,133,812
Fixed assets		3,194,533
Intangible assets		465,007
Liabilities		(1,977,822	)
Accumulated other comprehensive income		(651,751	)
		2,243,225
Loss from disposal of discontinued component, net of income tax	$	(1,340,795	)

XML 23 R15.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2022

Accounting Policies [Abstract]

Schedule of reconciliation of the deconsolidation

	Amount
Selling price	$	902,430
Disposed assets and liabilities:
Cash		79,446
Current assets		1,133,812
Fixed assets		3,194,533
Intangible assets		465,007
Liabilities		(1,977,822	)
Accumulated other comprehensive income		(651,751	)
		2,243,225
Loss from disposal of discontinued component, net of income tax	$	(1,340,795	)

XML 24 R16.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Tables)

6 Months Ended

Jun. 30, 2022

Schedule of payables due to related parties

	June 30,		December 31,
	2022		2021
Jinghe Zhang	$	-	$	3,999
Total	$	-	$	3,999

XML 25 R17.htm IDEA: XBRL DOCUMENT

Organization (Details) - USD ($)	Jun. 30, 2022	Jan. 31, 2021	Dec. 31, 2020
Organization (Details) [Line Items]
Cash (in Dollars)	$ 119,070		$ 119,070
Common stock issued			10,000
Per share (in Dollars per share)			$ 0.45
Shares issued		17,408,000
Crystal Globe [Member]
Organization (Details) [Line Items]
Common stock issued		2,646,000
Per share (in Dollars per share)		$ 0.045
Cash received (in Dollars)		$ 119,070
Shares issued		17,408,000

XML 26 R18.htm IDEA: XBRL DOCUMENT

Going Concern (Details) - USD ($)	6 Months Ended
Going Concern (Details) - USD ($)	Jun. 30, 2022	Jun. 30, 2021
Going Concern (Details) [Line Items]
Incurred net losses	$ 40,629	$ 96,557
Accumulated deficit	$ 7,400,000

XML 27 R19.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details) - USD ($)	1 Months Ended		6 Months Ended
	Jan. 31, 2021	Nov. 20, 2020	Jun. 30, 2022
Summary of Significant Accounting Policies (Details) [Line Items]
Shareholder holding percentage			86.81%
Cash consideration per share (in Dollars per share)			$ 0.045
Common stock, shares outstanding		20,054,000
Transaction loss (in Dollars)			$ 1,340,795
Cash received (in Dollars)	$ 119,070
Payment per share (in Dollars per share)	$ 0.045
Offset shares	17,408,000
Joway Health [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Common stock shares	2,646,000
Crystal Globe [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Common stock shares	17,408,000

XML 28 R20.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details) - Schedule of reconciliation of the deconsolidation	Jun. 30, 2022 USD ($)
Schedule of reconciliation of the deconsolidation [Abstract]
Selling price	$ 902,430
Cash	79,446
Current assets	1,133,812
Fixed assets	3,194,533
Intangible assets	465,007
Liabilities	(1,977,822)
Accumulated other comprehensive income	(651,751)
Loss from disposal of discontinued component, gross of income tax	2,243,225
Loss from disposal of discontinued component, net of income tax	$ (1,340,795)

XML 29 R21.htm IDEA: XBRL DOCUMENT

Other Payables (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Other Payables [Abstract]
Other payables	$ 143,682	$ 103,053

XML 30 R22.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details) - Jinghe Zhang [Member] - USD ($)	3 Months Ended	6 Months Ended
	Mar. 31, 2021	Jun. 30, 2022	Dec. 31, 2021
Related Party Transactions (Details) [Line Items]
Related party released amount	$ 3,397	$ 3,999.19
Unpaid principle amount advance		$ 0	$ 3,999

XML 31 R23.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details) - Schedule of payables due to related parties - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Related Party Transaction [Line Items]
Total		$ 3,999
Jinghe Zhang [Member]
Related Party Transaction [Line Items]
Total		$ 3,999

- Definition

The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(C))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(3)(a)(2))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

XML 32 f10q0622_jowayhealth_htm.xml IDEA: XBRL DOCUMENT 0001263364 2022-01-01 2022-06-30 0001263364 2022-08-09 0001263364 2022-06-30 0001263364 2021-12-31 0001263364 2022-04-01 2022-06-30 0001263364 2021-04-01 2021-06-30 0001263364 2021-01-01 2021-06-30 0001263364 2020-12-31 0001263364 2021-06-30 0001263364 gtvi:CrystalGlobeMember 2021-01-31 0001263364 2021-01-31 0001263364 2020-11-01 2020-11-20 0001263364 2021-01-01 2021-01-31 0001263364 gtvi:JowayHealthMember 2021-01-31 0001263364 gtvi:CrystalGlobeMember 2021-01-31 0001263364 gtvi:JingheZhangMember 2022-01-01 2022-06-30 0001263364 gtvi:JingheZhangMember 2021-01-01 2021-03-31 0001263364 gtvi:JingheZhangMember 2022-06-30 0001263364 gtvi:JingheZhangMember 2021-12-31 0001263364 gtvi:JingheZhangMember 2022-06-30 0001263364 gtvi:JingheZhangMember 2021-12-31 shares iso4217:USD iso4217:USD shares pure 10-Q true 2022-06-30 2022 false 333-108715 Joway Health Industries Group Inc. NV 98-0221494 600 South 3rd Street Las Vegas NV 89101 (702) 384-1990 Yes Yes Non-accelerated Filer true false true 20054000

143682

103053

3999

143682

107052

0.001

1000000

0.001

200000000

20054000

20054

7232861

7228862

-7396597

-7355968

-143682

-107052

-30295

-13132

-40629

-96557

30295

13132

40629

96557

-30295

-13132

-40629

-96557

-30295

-13132

-40629

-96557

-30295

-13132

-40629

-96557

-30295

-13132

-40629

-96557

20054000

-40629

-96557

119070 119070 40629 29560

-66997

66997

NOTE 1 – ORGANIZATION Joway Health Industries Group Inc. is herein referred to as “Joway Health”, the “Company,” “we” and “us”. Joway Health (formerly G2 Ventures, Inc.) was originally incorporated under the laws of the State of Nevada on March 21, 2003. On November 20, 2020, Joway Health entered into a Merger Agreement (the “Merger Agreement”) with Dynamic Elite International Limited, a British Virgin Islands company and a wholly-owned subsidiary of the Company (“Dynamic Elite”), Crystal Globe Limited, a British Virgin Islands company (“Parent”) and Joway Merger Subsidiary Limited, a British Virgin Islands company and a wholly-owned subsidiary of Parent (“Merger Sub”). Pursuant to the terms of the Merger Agreement, Merger Sub merged with and into Dynamic Elite (the “Merger”), with Dynamic Elite continuing as the surviving corporation as a wholly-owned subsidiary of Parent. The special committee of the Board of Directors of the Company unanimously approved the Merger Agreement and the transactions contemplated thereby. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”) and as a result of the Merger, the ordinary shares of common stock of Dynamic Elite issued and outstanding immediately prior to the Effective Time, all of which are held by the Company, were cancelled and extinguished in consideration for $119,070 in cash (the “Merger Consideration”). The Company distributed the Merger Consideration to its shareholders (other than to Parent) in an amount equal to such shareholder’s proportionate share of the Merger Consideration based on such shareholders’ percentage of the outstanding common stock of the Company. In addition, the Company received a fairness opinion from an investment banker opining that the Merger Consideration was fair, from a financial point of view, to the shareholders of the Company. As of December 31, 2020, the Effective Time of the Merger, the 10,000 ordinary shares of common stock of Dynamic Elite issued and outstanding immediately which were held by the Company, were cancelled for $119,070 in cash as Merger Consideration, or $0.45 per share. In January 2021, the Company had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders, other than Crystal Globe, which represented 2,646,000 shares of our common stock. Since the remaining 17,408,000 shares of our common stock was owned by Crystal Globe, the $0.045 per share payment for the 17,408,000 shares was offset and Crystal Globe did not receive any cash payment in connection with the Merger. On December 31, 2020, upon the Company completed the Merger Agreement with Crystal Globe, Joway Health became a “shell company” (as such term is defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Going forward, the Company intends to seek, investigate and, if such investigation warrants, engage in a business combination with a private entity whose business presents an opportunity for the Company’s stockholders.

119070

10000

119070

0.45

119070

2646000

17408000

0.045

17408000

NOTE 2 – GOING CONCERN The accompanying unaudited financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the discharge of liabilities in the normal course of business for the foreseeable future. As reflected in the accompanying unaudited financial statements, for the six months ended June 30, 2022 and 2021, we incurred net losses of $40,629 and $96,557, respectively. As of June 30, 2022, we had an accumulated deficit of $7.4 million. Management believes these factors raise substantial doubt about our ability to continue as a going concern for the next twelve months. The continuation of our Company as a going concern through the next twelve months is dependent upon the continued financial support from our stockholders or external financing. Management believes that our existing stockholders will provide the additional cash to meet our obligations as they become due. These conditions raise substantial doubt about our company’s ability to continue as a going concern. These financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of these uncertainties. Management believes that the actions presently being taken to obtain additional funding and implement its strategic plan provides the opportunity for our company to continue as a going concern.

40629 96557 7400000

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). After the consummation of the Merger as of December 31, 2020, the Company’s functional currency is USD. Use of Estimates The preparation of the financial statements is in conformity with generally accepted accounting principles in the United States of America, which require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made. Actual results could differ from those estimates. Other Comprehensive Income Other comprehensive income is defined as the change in equity during the period from transactions and other events, excluding the changes resulting from investments by owners and distributions to owners, and is not included in the computation of income tax expense or benefit. Accumulated other comprehensive income represents the accumulated balance of foreign currency translation adjustments. Concentrations of Credit Risk As a result of the consummation of the Merger, as of December 31, 2020, the Company became a shell company, as that term is defined in Rule 12b-2 of the Exchange Act of 1934, as amended (the “Exchange Act”). Going forward, our main business operations consist of seeking a business combination with a private entity whose business would present an opportunity for its shareholders. Fair Value of Financial Instruments Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">●</td> <td style="text-align: justify">Level 1—defined as observable inputs such as quoted prices in active markets for identical assets or liabilities;</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">●</td> <td style="text-align: justify">Level 2—defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">●</td> <td style="text-align: justify">Level 3—defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</td></tr> </table> The carrying amounts reported in the balance sheets for cash, accounts receivable, other receivable, accounts payable, other payable, and amounts due from related parties generally approximate their fair market values based on the short-term maturity of these instruments. ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments. Revenue Recognition The Company recognizes revenue when it satisfies a performance obligation by transferring a promised good or service to a customer or the customer obtains control of that asset, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those promised goods or services. After the consummation of the Merger as of December 31, 2020, the Company did not report any revenue for the year ended December 31, 2021 or the first half year ending June 30, 2022. Income Taxes The Company accounts for income taxes in accordance with FASB ASC 740 “Income Taxes” (formerly SFAS No. 109 Accounting for Income Taxes), which is an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. ASC 740 additionally requires the establishment of a valuation allowance to reflect the likelihood of realization of deferred tax assets. Realization of deferred tax assets is dependent upon future earnings, if any, of which the timing and amount are uncertain. According to ASC 740, the evaluation of a tax position is a two-step process. The first step is to determine whether it is more likely than not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigation based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50% likelihood of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer met. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition. Basic and Diluted Earnings per Share The Company reports earnings per share in accordance with FASB ASC 260 “Earnings per share”. The Company’s basic earnings per share are computed using the weighted average number of shares outstanding for the periods presented. Diluted earnings per share are computed based on the assumption that any dilutive options or warrants were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, the Company’s outstanding stock warrants are assumed to be exercised, and funds thus obtained were assumed to be used to purchase common stock at the average market price during the period. There were no dilutive instruments outstanding during the three month and six month periods ended June 30, 2022 and 2021. Recently Issued Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company adopted the standard in 2021. Adoption of the standard did not have a significant impact on the Company’s statement of earnings in 2021. Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s consolidated financial statements upon adoption. Deconsolidation On November 20, 2020, Joway Health entered into a Merger Agreement (the “Merger Agreement”) with Dynamic Elite International Limited, a British Virgin Islands company and a wholly-owned subsidiary of the Company (“Dynamic Elite”), Crystal Globe Limited, a British Virgin Islands company (“Crystal Globe”) and Joway Merger Subsidiary Limited, a British Virgin Islands company and a wholly-owned subsidiary of Crystal Globe (“Merger Sub”). The Merger Agreement provides that, upon the terms and subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will be merged with and into Dynamic Elite (the “Merger”), with Dynamic Elite continuing as the surviving corporation as a wholly-owned subsidiary of Crystal Globe. Crystal Globe, as the majority shareholder holding approximately 86.81% of the Company, is also the sole shareholder of Dynamic Elite after the Merger. Mr. Jinghe Zhang, as the former President, former Chief Executive Officer, former Chairman and Director, and the majority beneficial owner of the Company, also serves as sole shareholder and executive director of Crystal Globe. As a result, the Company and Dynamic Elite are under common control of Crystal Globe and Mr. Jinghe Zhang. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”) and as a result of the Merger, the ordinary shares of common stock of Dynamic Elite issued and outstanding immediately prior to the Effective Time, all of which are held by the Company, will be cancelled and extinguished. In accordance with the Merger Agreement, Crystal Globe has offered a cash consideration of $0.045 per share for outstanding shares of Joway Health’s common stock (the “Merger Consideration”). As of November 20, 2020, Joway Health reported 20,054,000 shares of common stock outstanding. As a result, Joway Health recognized a loss of $1,340,795 from this transaction. In January 2021, Joway Health had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders, other than Crystal Globe, which represents 2,646,000 shares of Joway Health’s common stock. Since the remaining 17,408,000 shares of Joway Health’s common stock is owned by Crystal Globe, the $0.045 per share payment for the 17,408,000 shares is offset. The following is a reconciliation of the deconsolidation: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify; padding-bottom: 4pt">Selling price</td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">902,430</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Disposed assets and liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Cash</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">79,446</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,133,812</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Fixed assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,194,533</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">465,007</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,977,822</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Accumulated other comprehensive income</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(651,751</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,243,225</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 4pt">Loss from disposal of discontinued component, net of income tax</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,340,795</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> </table>

Basis of Presentation The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”). After the consummation of the Merger as of December 31, 2020, the Company’s functional currency is USD.

Use of Estimates The preparation of the financial statements is in conformity with generally accepted accounting principles in the United States of America, which require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made. Actual results could differ from those estimates.

Other Comprehensive Income Other comprehensive income is defined as the change in equity during the period from transactions and other events, excluding the changes resulting from investments by owners and distributions to owners, and is not included in the computation of income tax expense or benefit. Accumulated other comprehensive income represents the accumulated balance of foreign currency translation adjustments.

Concentrations of Credit Risk As a result of the consummation of the Merger, as of December 31, 2020, the Company became a shell company, as that term is defined in Rule 12b-2 of the Exchange Act of 1934, as amended (the “Exchange Act”). Going forward, our main business operations consist of seeking a business combination with a private entity whose business would present an opportunity for its shareholders.

Fair Value of Financial Instruments Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">●</td> <td style="text-align: justify">Level 1—defined as observable inputs such as quoted prices in active markets for identical assets or liabilities;</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">●</td> <td style="text-align: justify">Level 2—defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">●</td> <td style="text-align: justify">Level 3—defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</td></tr> </table> The carrying amounts reported in the balance sheets for cash, accounts receivable, other receivable, accounts payable, other payable, and amounts due from related parties generally approximate their fair market values based on the short-term maturity of these instruments. ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments.

Revenue Recognition The Company recognizes revenue when it satisfies a performance obligation by transferring a promised good or service to a customer or the customer obtains control of that asset, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those promised goods or services. After the consummation of the Merger as of December 31, 2020, the Company did not report any revenue for the year ended December 31, 2021 or the first half year ending June 30, 2022.

Income Taxes The Company accounts for income taxes in accordance with FASB ASC 740 “Income Taxes” (formerly SFAS No. 109 Accounting for Income Taxes), which is an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the Company’s financial statements or tax returns. ASC 740 additionally requires the establishment of a valuation allowance to reflect the likelihood of realization of deferred tax assets. Realization of deferred tax assets is dependent upon future earnings, if any, of which the timing and amount are uncertain. According to ASC 740, the evaluation of a tax position is a two-step process. The first step is to determine whether it is more likely than not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigation based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefit to be recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50% likelihood of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer met. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition.

Basic and Diluted Earnings per Share The Company reports earnings per share in accordance with FASB ASC 260 “Earnings per share”. The Company’s basic earnings per share are computed using the weighted average number of shares outstanding for the periods presented. Diluted earnings per share are computed based on the assumption that any dilutive options or warrants were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, the Company’s outstanding stock warrants are assumed to be exercised, and funds thus obtained were assumed to be used to purchase common stock at the average market price during the period. There were no dilutive instruments outstanding during the three month and six month periods ended June 30, 2022 and 2021.

Recently Issued Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company adopted the standard in 2021. Adoption of the standard did not have a significant impact on the Company’s statement of earnings in 2021. Other accounting standards that have been issued or proposed by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on the Company’s consolidated financial statements upon adoption.

Deconsolidation On November 20, 2020, Joway Health entered into a Merger Agreement (the “Merger Agreement”) with Dynamic Elite International Limited, a British Virgin Islands company and a wholly-owned subsidiary of the Company (“Dynamic Elite”), Crystal Globe Limited, a British Virgin Islands company (“Crystal Globe”) and Joway Merger Subsidiary Limited, a British Virgin Islands company and a wholly-owned subsidiary of Crystal Globe (“Merger Sub”). The Merger Agreement provides that, upon the terms and subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will be merged with and into Dynamic Elite (the “Merger”), with Dynamic Elite continuing as the surviving corporation as a wholly-owned subsidiary of Crystal Globe. Crystal Globe, as the majority shareholder holding approximately 86.81% of the Company, is also the sole shareholder of Dynamic Elite after the Merger. Mr. Jinghe Zhang, as the former President, former Chief Executive Officer, former Chairman and Director, and the majority beneficial owner of the Company, also serves as sole shareholder and executive director of Crystal Globe. As a result, the Company and Dynamic Elite are under common control of Crystal Globe and Mr. Jinghe Zhang. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the “Effective Time”) and as a result of the Merger, the ordinary shares of common stock of Dynamic Elite issued and outstanding immediately prior to the Effective Time, all of which are held by the Company, will be cancelled and extinguished. In accordance with the Merger Agreement, Crystal Globe has offered a cash consideration of $0.045 per share for outstanding shares of Joway Health’s common stock (the “Merger Consideration”). As of November 20, 2020, Joway Health reported 20,054,000 shares of common stock outstanding. As a result, Joway Health recognized a loss of $1,340,795 from this transaction. In January 2021, Joway Health had received $119,070 from Crystal Globe and distributed proportionately to the Company’s minority shareholders, other than Crystal Globe, which represents 2,646,000 shares of Joway Health’s common stock. Since the remaining 17,408,000 shares of Joway Health’s common stock is owned by Crystal Globe, the $0.045 per share payment for the 17,408,000 shares is offset. The following is a reconciliation of the deconsolidation: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify; padding-bottom: 4pt">Selling price</td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">902,430</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Disposed assets and liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Cash</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">79,446</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,133,812</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Fixed assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,194,533</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">465,007</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,977,822</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Accumulated other comprehensive income</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(651,751</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,243,225</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 4pt">Loss from disposal of discontinued component, net of income tax</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,340,795</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> </table> 0.8681 0.045

20054000

1340795

119070 2646000 17408000 0.045 17408000

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify; padding-bottom: 4pt">Selling price</td><td style="width: 1%; padding-bottom: 4pt"> </td> <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">902,430</td><td style="width: 1%; padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Disposed assets and liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Cash</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">79,446</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Current assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,133,812</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Fixed assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,194,533</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify">Intangible assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">465,007</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,977,822</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 1.5pt">Accumulated other comprehensive income</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(651,751</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,243,225</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: justify; padding-bottom: 4pt">Loss from disposal of discontinued component, net of income tax</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,340,795</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> </table>

902430

79446

1133812

3194533

465007

1977822

-651751

2243225 -1340795

NOTE 4 – OTHER PAYABLES As of June 30, 2022 and December 31, 2021, the Company reported $143,682 and $103,053 as its other payables, respectively. The other payables mainly consist of payables for professional services, including audit, legal, and financial statement filing services.

143682

103053

NOTE 5 – RELATED PARTY TRANSACTIONS Payables due to related parties consist of the following: <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">June 30,</td><td style="white-space: nowrap; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">December 31,</td><td style="white-space: nowrap; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Jinghe Zhang</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70"> -</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,999</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,999</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> The amounts owed to related parties are non-interest bearing and have no specified repayment terms. Transactions with Jinghe Zhang The Company was a shell company and has no cash, Mr. Jinghe Zhang, our former President, former Chief Executive Officer and director, agreed to advance operating capital to the Company. For the three months ended March 31, 2022, Mr. Jinghe Zhang released the Company from $3,999.19 of indebtedness owed to him. For the three months ended March 31, 2021, the Company received $3,397 from Mr. Jinghe Zhang. As of June 30, 2022 and December 31, 2021, the total unpaid principal balance due to Mr. Jinghe Zhang for advances was $0 and $3,999, respectively.

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">June 30,</td><td style="white-space: nowrap; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold"> </td> <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">December 31,</td><td style="white-space: nowrap; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Jinghe Zhang</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70"> -</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,999</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-71">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,999</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>

3999

3999.19 3397 0 3999

NOTE 6 – INCOME TAXES Upon the Company executed the Merger Agreement on December 31, 2020, no provision was made for federal income taxes since the Company has significant net operating losses. The Company’s income tax returns since inception are subject to audit by regulatory authorities. Changes in tax laws and rates could also affect recorded deferred tax assets and liabilities in the future. Management is not aware of any such changes that would have a material effect on the Company’s results of operations, cash flows or financial position. The calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations. FASB ASC Topic 740, Income Taxes provides that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, based on the technical merits. ASC Topic 740 also provides guidance on measurement, derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. We recognize tax liabilities in accordance with ASC Topic 740 and we adjust these liabilities when our judgment changes as a result of the evaluation of new information not previously available. Due to the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from our current estimate of the tax liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which they are determined.

NOTE 7 – SUBSEQUENT EVENTS None

20054000

false --12-31 Q2 0001263364

EXCEL 33 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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endXML 34 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 35 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 36 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 21 123 1 false 5 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://jowayhealth.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Balance Sheets Sheet http://jowayhealth.com/role/ConsolidatedBalanceSheet Balance Sheets Statements 2 false false R3.htm 002 - Statement - Balance Sheets (Parentheticals) Sheet http://jowayhealth.com/role/ConsolidatedBalanceSheet_Parentheticals Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://jowayhealth.com/role/ConsolidatedIncomeStatement Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 004 - Statement - Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals) Sheet http://jowayhealth.com/role/ConsolidatedIncomeStatement_Parentheticals Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals) Statements 5 false false R6.htm 005 - Statement - Statements of Cash Flows (Unaudited) Sheet http://jowayhealth.com/role/ConsolidatedCashFlow Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 006 - Disclosure - Organization Sheet http://jowayhealth.com/role/Organization Organization Notes 7 false false R8.htm 007 - Disclosure - Going Concern Sheet http://jowayhealth.com/role/GoingConcern Going Concern Notes 8 false false R9.htm 008 - Disclosure - Summary of Significant Accounting Policies Sheet http://jowayhealth.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 009 - Disclosure - Other Payables Sheet http://jowayhealth.com/role/OtherPayables Other Payables Notes 10 false false R11.htm 010 - Disclosure - Related Party Transactions Sheet http://jowayhealth.com/role/RelatedPartyTransactions Related Party Transactions Notes 11 false false R12.htm 011 - Disclosure - Income Taxes Sheet http://jowayhealth.com/role/IncomeTaxes Income Taxes Notes 12 false false R13.htm 012 - Disclosure - Subsequent Events Sheet http://jowayhealth.com/role/SubsequentEvents Subsequent Events Notes 13 false false R14.htm 013 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://jowayhealth.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://jowayhealth.com/role/SummaryofSignificantAccountingPolicies 14 false false R15.htm 014 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://jowayhealth.com/role/SummaryofSignificantAccountingPolicies 15 false false R16.htm 015 - Disclosure - Related Party Transactions (Tables) Sheet http://jowayhealth.com/role/RelatedPartyTransactionsTables Related Party Transactions (Tables) Tables http://jowayhealth.com/role/RelatedPartyTransactions 16 false false R17.htm 016 - Disclosure - Organization (Details) Sheet http://jowayhealth.com/role/OrganizationDetails Organization (Details) Details http://jowayhealth.com/role/Organization 17 false false R18.htm 017 - Disclosure - Going Concern (Details) Sheet http://jowayhealth.com/role/GoingConcernDetails Going Concern (Details) Details http://jowayhealth.com/role/GoingConcern 18 false false R19.htm 018 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesTables 19 false false R20.htm 019 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of reconciliation of the deconsolidation Sheet http://jowayhealth.com/role/ScheduleofreconciliationofthedeconsolidationTable Summary of Significant Accounting Policies (Details) - Schedule of reconciliation of the deconsolidation Details http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesTables 20 false false R21.htm 020 - Disclosure - Other Payables (Details) Sheet http://jowayhealth.com/role/OtherPayablesDetails Other Payables (Details) Details http://jowayhealth.com/role/OtherPayables 21 false false R22.htm 021 - Disclosure - Related Party Transactions (Details) Sheet http://jowayhealth.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://jowayhealth.com/role/RelatedPartyTransactionsTables 22 false false R23.htm 022 - Disclosure - Related Party Transactions (Details) - Schedule of payables due to related parties Sheet http://jowayhealth.com/role/ScheduleofpayablesduetorelatedpartiesTable Related Party Transactions (Details) - Schedule of payables due to related parties Details http://jowayhealth.com/role/RelatedPartyTransactionsTables 23 false false All Reports Book All Reports f10q0622_jowayhealth.htm f10q0622ex31-1_jowayhealth.htm f10q0622ex32-1_jowayhealth.htm gtvi-20220630.xsd gtvi-20220630_cal.xml gtvi-20220630_def.xml gtvi-20220630_lab.xml gtvi-20220630_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 39 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f10q0622_jowayhealth.htm": { "axisCustom": 0, "axisStandard": 4, "contextCount": 21, "dts": { "calculationLink": { "local": [ "gtvi-20220630_cal.xml" ] }, "definitionLink": { "local": [ "gtvi-20220630_def.xml" ] }, "inline": { "local": [ "f10q0622_jowayhealth.htm" ] }, "labelLink": { "local": [ "gtvi-20220630_lab.xml" ] }, "presentationLink": { "local": [ "gtvi-20220630_pre.xml" ] }, "schema": { "local": [ "gtvi-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd" ] } }, "elementCount": 168, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 70, "http://jowayhealth.com/20220630": 2, "http://xbrl.sec.gov/dei/2022": 4, "total": 76 }, "keyCustom": 17, "keyStandard": 106, "memberCustom": 3, "memberStandard": 0, "nsprefix": "gtvi", "nsuri": "http://jowayhealth.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://jowayhealth.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDividendPaymentRestrictionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Other Payables", "role": "http://jowayhealth.com/role/OtherPayables", "shortName": "Other Payables", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDividendPaymentRestrictionsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Related Party Transactions", "role": "http://jowayhealth.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Income Taxes", "role": "http://jowayhealth.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Subsequent Events", "role": "http://jowayhealth.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Accounting Policies, by Policy (Policies)", "role": "http://jowayhealth.com/role/AccountingPoliciesByPolicy", "shortName": "Accounting Policies, by Policy (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Related Party Transactions (Tables)", "role": "http://jowayhealth.com/role/RelatedPartyTransactionsTables", "shortName": "Related Party Transactions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RestrictedCash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Organization (Details)", "role": "http://jowayhealth.com/role/OrganizationDetails", "shortName": "Organization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RestrictedCash", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "gtvi:IncurredNetLosses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Going Concern (Details)", "role": "http://jowayhealth.com/role/GoingConcernDetails", "shortName": "Going Concern (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "gtvi:IncurredNetLosses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c0", "decimals": "4", "first": true, "lang": null, "name": "gtvi:ShareholderHoldingPercentage", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Summary of Significant Accounting Policies (Details)", "role": "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c0", "decimals": "4", "first": true, "lang": null, "name": "gtvi:ShareholderHoldingPercentage", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Balance Sheets", "role": "http://jowayhealth.com/role/ConsolidatedBalanceSheet", "shortName": "Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "gtvi:SellingPrice", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of reconciliation of the deconsolidation", "role": "http://jowayhealth.com/role/ScheduleofreconciliationofthedeconsolidationTable", "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of reconciliation of the deconsolidation", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "gtvi:SellingPrice", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DividendPaymentsRestrictionsScheduleStatutoryCapitalAndSurplus1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Other Payables (Details)", "role": "http://jowayhealth.com/role/OtherPayablesDetails", "shortName": "Other Payables (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DividendPaymentsRestrictionsScheduleStatutoryCapitalAndSurplus1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c16", "decimals": "0", "first": true, "lang": null, "name": "gtvi:DueFromRelatedPartiesForContinuingOperatingComponent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Related Party Transactions (Details)", "role": "http://jowayhealth.com/role/RelatedPartyTransactionsDetails", "shortName": "Related Party Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c16", "decimals": "0", "first": true, "lang": null, "name": "gtvi:DueFromRelatedPartiesForContinuingOperatingComponent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DueFromRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Related Party Transactions (Details) - Schedule of payables due to related parties", "role": "http://jowayhealth.com/role/ScheduleofpayablesduetorelatedpartiesTable", "shortName": "Related Party Transactions (Details) - Schedule of payables due to related parties", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DueFromRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c2", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Balance Sheets (Parentheticals)", "role": "http://jowayhealth.com/role/ConsolidatedBalanceSheet_Parentheticals", "shortName": "Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c2", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPershares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Statements of Operations and Comprehensive Loss (Unaudited)", "role": "http://jowayhealth.com/role/ConsolidatedIncomeStatement", "shortName": "Statements of Operations and Comprehensive Loss (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c4", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals)", "role": "http://jowayhealth.com/role/ConsolidatedIncomeStatement_Parentheticals", "shortName": "Statements of Operations and Comprehensive Loss (Unaudited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Statements of Cash Flows (Unaudited)", "role": "http://jowayhealth.com/role/ConsolidatedCashFlow", "shortName": "Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "006 - Disclosure - Organization", "role": "http://jowayhealth.com/role/Organization", "shortName": "Organization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Going Concern", "role": "http://jowayhealth.com/role/GoingConcern", "shortName": "Going Concern", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Summary of Significant Accounting Policies", "role": "http://jowayhealth.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0622_jowayhealth.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 5, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://jowayhealth.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "gtvi_AccumulatedDeficit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated deficit.", "label": "AccumulatedDeficit", "terseLabel": "Accumulated deficit" } } }, "localname": "AccumulatedDeficit", "nsuri": "http://jowayhealth.com/20220630", "presentation": [ "http://jowayhealth.com/role/GoingConcernDetails" ], "xbrltype": "monetaryItemType" }, "gtvi_CashConsiderationPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash consideration per share.", "label": "CashConsiderationPerShare", "terseLabel": "Cash consideration per share (in Dollars per share)" } } }, "localname": "CashConsiderationPerShare", "nsuri": "http://jowayhealth.com/20220630", "presentation": [ "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "perShareItemType" }, "gtvi_CashReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received.", "label": "CashReceived", "terseLabel": "Cash received (in Dollars)" } } }, "localname": "CashReceived", "nsuri": "http://jowayhealth.com/20220630", "presentation": [ "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "gtvi_CommonStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock shares.", "label": "CommonStockShares", "terseLabel": "Common stock shares" } } }, "localname": "CommonStockShares", "nsuri": "http://jowayhealth.com/20220630", "presentation": [ "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "gtvi_CrystalGlobeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Crystal globe.", "label": "CrystalGlobeMember", "terseLabel": "Crystal Globe [Member]" } } }, "localname": "CrystalGlobeMember", "nsuri": "http://jowayhealth.com/20220630", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails", "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "gtvi_DeconsolidationPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deconsolidation Policy Text Block.", "label": "DeconsolidationPolicyTextBlock", "terseLabel": "Deconsolidation" } } }, "localname": "DeconsolidationPolicyTextBlock", "nsuri": "http://jowayhealth.com/20220630", "presentation": [ "http://jowayhealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "gtvi_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://jowayhealth.com/20220630", "xbrltype": "stringItemType" }, "gtvi_DueFromRelatedPartiesForContinuingOperatingComponent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Due from related parties for continuing operating component.", "label": "DueFromRelatedPartiesForContinuingOperatingComponent", "terseLabel": "Related party released amount" } } }, "localname": "DueFromRelatedPartiesForContinuingOperatingComponent", "nsuri": "http://jowayhealth.com/20220630", "presentation": [ "http://jowayhealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "gtvi_GoingConcernDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Going Concern (Details) [Line Items]" } } }, "localname": "GoingConcernDetailsLineItems", "nsuri": "http://jowayhealth.com/20220630", "presentation": [ "http://jowayhealth.com/role/GoingConcernDetails" ], "xbrltype": "stringItemType" }, "gtvi_GoingConcernDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Going Concern (Details) [Table]" } } }, "localname": "GoingConcernDetailsTable", "nsuri": "http://jowayhealth.com/20220630", "presentation": [ "http://jowayhealth.com/role/GoingConcernDetails" ], "xbrltype": "stringItemType" }, "gtvi_GoingConcernLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Going Concern [Abstract]" } } }, "localname": "GoingConcernLineItems", "nsuri": "http://jowayhealth.com/20220630", "presentation": [ "http://jowayhealth.com/role/GoingConcern" ], "xbrltype": "stringItemType" }, "gtvi_GoingConcernTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Going Concern [Table]" } } }, "localname": "GoingConcernTable", "nsuri": "http://jowayhealth.com/20220630", "presentation": [ "http://jowayhealth.com/role/GoingConcern" ], "xbrltype": "stringItemType" }, "gtvi_IncreaseDecreaseInOtherPayable": { "auth_ref": [], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "IncreaseDecreaseInOtherPayable", "terseLabel": "Other payables" } } }, "localname": "IncreaseDecreaseInOtherPayable", "nsuri": "http://jowayhealth.com/20220630", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "gtvi_IncreaseDecreaseInSpecialDividendPayables": { "auth_ref": [], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Special dividend payable.", "label": "IncreaseDecreaseInSpecialDividendPayables", "negatedLabel": "Special dividend payable" } } }, "localname": "IncreaseDecreaseInSpecialDividendPayables", "nsuri": "http://jowayhealth.com/20220630", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "gtvi_IncurredNetLosses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Incurred net losses.", "label": "IncurredNetLosses", "terseLabel": "Incurred net losses" } } }, "localname": "IncurredNetLosses", "nsuri": "http://jowayhealth.com/20220630", "presentation": [ "http://jowayhealth.com/role/GoingConcernDetails" ], "xbrltype": "monetaryItemType" }, "gtvi_JingheZhangMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Jinghe zhang.", "label": "JingheZhangMember", "terseLabel": "Jinghe Zhang [Member]" } } }, "localname": "JingheZhangMember", "nsuri": "http://jowayhealth.com/20220630", "presentation": [ "http://jowayhealth.com/role/RelatedPartyTransactionsDetails", "http://jowayhealth.com/role/ScheduleofpayablesduetorelatedpartiesTable" ], "xbrltype": "domainItemType" }, "gtvi_JowayHealthMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "JowayHealthMember", "terseLabel": "Joway Health [Member]" } } }, "localname": "JowayHealthMember", "nsuri": "http://jowayhealth.com/20220630", "presentation": [ "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "gtvi_LossFromDisposalOfDiscontinuedComponentGross": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Loss from disposal of discontinued component, gross.", "label": "LossFromDisposalOfDiscontinuedComponentGross", "terseLabel": "Loss from disposal of discontinued component, gross of income tax" } } }, "localname": "LossFromDisposalOfDiscontinuedComponentGross", "nsuri": "http://jowayhealth.com/20220630", "presentation": [ "http://jowayhealth.com/role/ScheduleofreconciliationofthedeconsolidationTable" ], "xbrltype": "monetaryItemType" }, "gtvi_LossFromDisposalOfDiscontinuedComponentNetOfIncomeTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Loss from disposal of discontinued component, net of income tax.", "label": "LossFromDisposalOfDiscontinuedComponentNetOfIncomeTax", "terseLabel": "Loss from disposal of discontinued component, net of income tax" } } }, "localname": "LossFromDisposalOfDiscontinuedComponentNetOfIncomeTax", "nsuri": "http://jowayhealth.com/20220630", "presentation": [ "http://jowayhealth.com/role/ScheduleofreconciliationofthedeconsolidationTable" ], "xbrltype": "monetaryItemType" }, "gtvi_OffsetShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Offset shares.", "label": "OffsetShares", "terseLabel": "Offset shares" } } }, "localname": "OffsetShares", "nsuri": "http://jowayhealth.com/20220630", "presentation": [ "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "gtvi_OrganizationDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization (Details) [Line Items]" } } }, "localname": "OrganizationDetailsLineItems", "nsuri": "http://jowayhealth.com/20220630", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "stringItemType" }, "gtvi_OrganizationDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization (Details) [Table]" } } }, "localname": "OrganizationDetailsTable", "nsuri": "http://jowayhealth.com/20220630", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "stringItemType" }, "gtvi_PaymentPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Payment per share.", "label": "PaymentPerShare", "terseLabel": "Payment per share (in Dollars per share)" } } }, "localname": "PaymentPerShare", "nsuri": "http://jowayhealth.com/20220630", "presentation": [ "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "perShareItemType" }, "gtvi_ReceivableFromDisposalOfSubsidiaries": { "auth_ref": [], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Receivable from disposal of subsidiaries.", "label": "ReceivableFromDisposalOfSubsidiaries", "terseLabel": "Receivable from disposal of subsidiaries" } } }, "localname": "ReceivableFromDisposalOfSubsidiaries", "nsuri": "http://jowayhealth.com/20220630", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "gtvi_RelatedPartyTransactionsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions (Details) [Line Items]" } } }, "localname": "RelatedPartyTransactionsDetailsLineItems", "nsuri": "http://jowayhealth.com/20220630", "presentation": [ "http://jowayhealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "gtvi_RelatedPartyTransactionsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions (Details) [Table]" } } }, "localname": "RelatedPartyTransactionsDetailsTable", "nsuri": "http://jowayhealth.com/20220630", "presentation": [ "http://jowayhealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "gtvi_ScheduleOfPayablesDueToRelatedPartiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of payables due to related parties [Abstract]" } } }, "localname": "ScheduleOfPayablesDueToRelatedPartiesAbstract", "nsuri": "http://jowayhealth.com/20220630", "xbrltype": "stringItemType" }, "gtvi_ScheduleOfReconciliationOfTheDeconsolidationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of reconciliation of the deconsolidation [Abstract]" } } }, "localname": "ScheduleOfReconciliationOfTheDeconsolidationAbstract", "nsuri": "http://jowayhealth.com/20220630", "xbrltype": "stringItemType" }, "gtvi_SellingPrice": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Selling price.", "label": "SellingPrice", "terseLabel": "Selling price" } } }, "localname": "SellingPrice", "nsuri": "http://jowayhealth.com/20220630", "presentation": [ "http://jowayhealth.com/role/ScheduleofreconciliationofthedeconsolidationTable" ], "xbrltype": "monetaryItemType" }, "gtvi_ShareholderHoldingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shareholder holding percentage.", "label": "ShareholderHoldingPercentage", "terseLabel": "Shareholder holding percentage" } } }, "localname": "ShareholderHoldingPercentage", "nsuri": "http://jowayhealth.com/20220630", "presentation": [ "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "gtvi_SummaryofSignificantAccountingPoliciesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details) [Line Items]" } } }, "localname": "SummaryofSignificantAccountingPoliciesDetailsLineItems", "nsuri": "http://jowayhealth.com/20220630", "presentation": [ "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "gtvi_SummaryofSignificantAccountingPoliciesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details) [Table]" } } }, "localname": "SummaryofSignificantAccountingPoliciesDetailsTable", "nsuri": "http://jowayhealth.com/20220630", "presentation": [ "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "gtvi_UnpaidPrincipleAmountAdvance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Unpaid principle amount advance", "label": "UnpaidPrincipleAmountAdvance", "terseLabel": "Unpaid principle amount advance" } } }, "localname": "UnpaidPrincipleAmountAdvance", "nsuri": "http://jowayhealth.com/20220630", "presentation": [ "http://jowayhealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax": { "auth_ref": [ "r22", "r23", "r122" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ScheduleofreconciliationofthedeconsolidationTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r11", "r194" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in-capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_Assets": { "auth_ref": [ "r7", "r55", "r90", "r93", "r98", "r104", "r105", "r106", "r107", "r109", "r110", "r111", "r112", "r113", "r114", "r116", "r117", "r170", "r173", "r180", "r192", "r194", "r212", "r222" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r17", "r55", "r104", "r105", "r106", "r107", "r109", "r110", "r111", "r112", "r113", "r114", "r116", "r117", "r170", "r173", "r180", "r192", "r194" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "negatedLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "CURRENT ASSETS:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r124", "r125", "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ScheduleofreconciliationofthedeconsolidationTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r42", "r48", "r50" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "CASH, end of period", "periodStartLabel": "CASH, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r42", "r181" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "NET INCREASE IN CASH" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashUninsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.", "label": "Cash, Uninsured Amount", "terseLabel": "Cash received (in Dollars)" } } }, "localname": "CashUninsuredAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r21", "r215", "r226" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "COMMITMENTS" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in Dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r9", "r119" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r9", "r194" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock - par value $0.001; 200,000,000 shares authorized; 20,054,000 shares issued and outstanding at June 30, 2022 and December 31, 2021" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r25", "r27", "r28", "r34", "r218", "r228" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "COMPREHENSIVE LOSS" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "OTHER COMPREHENSIVE LOSS:" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Other Comprehensive Income" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r81", "r221" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentrations of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r52", "r172" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r38", "r197" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "COST OF REVENUES" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.", "label": "Deferred Tax Assets, Goodwill and Intangible Assets", "terseLabel": "Intangible assets" } } }, "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ScheduleofreconciliationofthedeconsolidationTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesRegulatoryAssets": { "auth_ref": [ "r158", "r159" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from regulatory assets.", "label": "Deferred Tax Liabilities, Regulatory Assets", "terseLabel": "Fixed assets" } } }, "localname": "DeferredTaxLiabilitiesRegulatoryAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ScheduleofreconciliationofthedeconsolidationTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfRestrictionsOnDividendsLoansAndAdvancesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Payables [Abstract]" } } }, "localname": "DisclosureOfRestrictionsOnDividendsLoansAndAdvancesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DividendPaymentsRestrictionsScheduleStatutoryCapitalAndSurplus1": { "auth_ref": [ "r234" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of statutory capital and surplus computed using prescribed or permitted statutory accounting practice.", "label": "Dividend Payments Restrictions Schedule, Statutory Capital and Surplus", "terseLabel": "Other payables" } } }, "localname": "DividendPaymentsRestrictionsScheduleStatutoryCapitalAndSurplus1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/OtherPayablesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueFromRelatedPartiesCurrent": { "auth_ref": [ "r3", "r10", "r58", "r108", "r110", "r111", "r115", "r116", "r117", "r187" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).", "label": "Due from Related Parties, Current", "terseLabel": "Total" } } }, "localname": "DueFromRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ScheduleofpayablesduetorelatedpartiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r18", "r58", "r108", "r110", "r111", "r115", "r116", "r117", "r187" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "terseLabel": "Due to related parties" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r35", "r61", "r62", "r63", "r64", "r65", "r68", "r70", "r72", "r73", "r74", "r77", "r78", "r176", "r177", "r219", "r229" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "NET LOSS PER COMMON SHARE, BASIC AND DILUTED: (in Dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r35", "r61", "r62", "r63", "r64", "r65", "r70", "r72", "r73", "r74", "r77", "r78", "r176", "r177", "r219", "r229" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "NET LOSS PER COMMON SHARE, DILUTED" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r75", "r76" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Basic and Diluted Earnings per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r181" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "EFFECT OF EXCHANGE RATE CHANGES ON CASH" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r178", "r179" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": { "auth_ref": [ "r46" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.", "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges", "negatedLabel": "General and administrative expenses" } } }, "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r36", "r55", "r90", "r92", "r94", "r97", "r99", "r104", "r105", "r106", "r107", "r110", "r111", "r112", "r113", "r114", "r116", "r117", "r180" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "GROSS PROFIT" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperations": { "auth_ref": [ "r37", "r47", "r61", "r62", "r63", "r64", "r71", "r74", "r169" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "terseLabel": "Net loss from continuing operations" } } }, "localname": "IncomeLossFromContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r32", "r90", "r92", "r94", "r97", "r99", "r210", "r216", "r220", "r230" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "LOSS BEFORE INCOME TAXES" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r56", "r153", "r154", "r157", "r161", "r163", "r165", "r166", "r167" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r57", "r66", "r67", "r89", "r152", "r162", "r164", "r231" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r29", "r150", "r151", "r154", "r155", "r156", "r160" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r44", "r49" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Income taxes paid" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r41", "r43", "r49" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r15", "r55", "r104", "r180", "r194", "r213", "r225" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity (deficit)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r5", "r20", "r55", "r104", "r105", "r106", "r107", "r110", "r111", "r112", "r113", "r114", "r116", "r117", "r171", "r173", "r174", "r180", "r192", "r193", "r194" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "CURRENT LIABILITIES:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r42" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r42" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "terseLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r42", "r45", "r47" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r0", "r24", "r26", "r30", "r33", "r47", "r55", "r60", "r61", "r62", "r63", "r64", "r66", "r67", "r71", "r90", "r92", "r94", "r97", "r99", "r104", "r105", "r106", "r107", "r110", "r111", "r112", "r113", "r114", "r116", "r117", "r177", "r180", "r217", "r227" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "NET LOSS" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonmonetaryTransactionGainLossRecognizedOnTransfer": { "auth_ref": [ "r182", "r183" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Disclosure of the difference in values (gain (loss)) between the nonmonetary assets or liabilities exchanged with another entity inclusive of boot (small monetary consideration).", "label": "Nonmonetary Transaction, Gain (Loss) Recognized on Transfer", "terseLabel": "Transaction loss (in Dollars)" } } }, "localname": "NonmonetaryTransactionGainLossRecognizedOnTransfer", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r39" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "OTHER LOSS, NET" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "OPERATING EXPENSES" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r90", "r92", "r94", "r97", "r99" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "LOSS FROM OPERATIONS" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r2", "r175" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "ORGANIZATION" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/Organization" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r16", "r194" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ScheduleofreconciliationofthedeconsolidationTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilities": { "auth_ref": [ "r214" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other.", "label": "Other Liabilities", "negatedLabel": "Liabilities" } } }, "localname": "OtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ScheduleofreconciliationofthedeconsolidationTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r19", "r194" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other payables" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingExpense": { "auth_ref": [ "r40" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to nonoperating activities, classified as other.", "label": "Other Nonoperating Expense", "negatedLabel": "Other expenses" } } }, "localname": "OtherNonoperatingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r8", "r118" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in Dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r8", "r118" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r8", "r194" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock - par value $0.001; 1,000,000 shares authorized; no shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": { "auth_ref": [], "calculation": { "http://jowayhealth.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.", "label": "Proceeds from (Repayments of) Related Party Debt", "terseLabel": "Due to related parties" } } }, "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r123", "r186", "r187" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ScheduleofpayablesduetorelatedpartiesTable" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r123", "r186", "r187", "r189" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/RelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ScheduleofpayablesduetorelatedpartiesTable" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r123", "r186", "r189", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ScheduleofpayablesduetorelatedpartiesTable" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r184", "r185", "r187", "r190", "r191" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r6", "r50", "r211", "r223" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Cash (in Dollars)" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r12", "r120", "r194", "r224", "r232", "r233" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r53", "r54" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r31", "r55", "r87", "r88", "r91", "r95", "r96", "r100", "r101", "r102", "r104", "r105", "r106", "r107", "r110", "r111", "r112", "r113", "r114", "r116", "r117", "r180", "r220" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "REVENUES" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfDividendPaymentRestrictionsTextBlock": { "auth_ref": [ "r235" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of statutory restrictions on the payment of dividends as prescribed by the National Association of Insurance Commissioners or state regulatory authorities.", "label": "Dividend Payment Restrictions [Text Block]", "terseLabel": "OTHER PAYABLES" } } }, "localname": "ScheduleOfDividendPaymentRestrictionsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/OtherPayables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r168" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of reconciliation of the deconsolidation" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r188", "r189" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ScheduleofpayablesduetorelatedpartiesTable" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.", "label": "Schedule of Related Party Transactions [Table Text Block]", "terseLabel": "Schedule of payables due to related parties" } } }, "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/RelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r124", "r125", "r126", "r127", "r128", "r129", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "terseLabel": "Shares issued" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued, Price Per Share", "terseLabel": "Per share (in Dollars per share)" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r51", "r59" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Shares, Other", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r9", "r13", "r14", "r55", "r103", "r104", "r180", "r194" ], "calculation": { "http://jowayhealth.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total stockholders\u2019 deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "STOCKHOLDERS\u2019 EQUITY (DEFICIT):" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r195", "r196" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "Substantial Doubt about Going Concern [Text Block]", "terseLabel": "GOING CONCERN" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/GoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "SUPPLEMENTAL DISCLOSURES:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r121" ], "lang": { "en-us": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Shares", "terseLabel": "Common stock issued" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/OrganizationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r79", "r80", "r82", "r83", "r84", "r85", "r86" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r69", "r74" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING, DILUTED" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r68", "r74" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING, BASIC AND DILUTED (in Shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://jowayhealth.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=51888271" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r167": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613673-111683" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r175": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "845", "URI": "https://asc.fasb.org/extlink&oid=126934811&loc=d3e32049-108421" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "845", "URI": "https://asc.fasb.org/extlink&oid=6457341&loc=d3e32102-108422" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r191": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r196": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=6486098&loc=d3e24708-158529" }, "r235": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "505", "Topic": "944", "URI": "https://asc.fasb.org/subtopic&trid=4738323" }, "r236": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r237": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r238": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r239": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.13)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r59": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" } }, "version": "2.1" } ZIP 40 0001213900-22-046308-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-22-046308-xbrl.zip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end